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ABSTRACT 
Background. The most appropriate endo-therapeutic approach to biliary anastomotic 
strictures is yet to be defined.  
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Aim. To retrospectively report on the endo-therapy of duct-to-duct anastomotic strictures 
during 2013 in Italy.  
Methods. Data were collected from 16 Endoscopy Units at the Italian Liver Transplantation 
Centers (BASALT study group). 
Results. Complete endo-therapy and follow-up data are available for 181 patients: 101 
treated with plastic multistenting, 26 with fully covered self-expandable metal stenting 
(SEMS) and 54 with single stenting. Radiological success was achieved for 145 patients 
(80%), i.e. 88% of plastic multistenting, 88% of SEMS and 61% of single stenting (p<0.001 vs 
plastic multistenting; p<0.05 vs SEMS)]. After first-line endo-therapy failure, the patients 
underwent a second-line endo-therapy with plastic multistenting for 25%, fully covered 
SEMS for 53% and single stenting for 22% of cases, and radiological success was achieved for 
84%, i.e. 100%, 85%, and 63% with plastic multistenting, SEMS and single stenting (p<0.05 vs 
plastic multistenting or SEMS), respectively. Procedure-related complications occurred in 
7.8% of ERCP. Overall clinical success was achieved in 87% of patients after a median follow-
up of 25 months. 
Conclusion. Plastic multistenting is confirmed as the preferred first-line treatment, while 
fully covered SEMS as rescue option for biliary anastomotic strictures. Single stenting has 
sub-optimal results and should be abandoned. 
 
Key words: Liver transplantation, biliary anastomotic stricture, ERCP, plastic multistenting, 
fully covered metal stenting. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Summary 
In the field of biliary anastomotic stricture after liver transplantation, a high rate of success 
is achieved by endoscopic therapies. 
 
Present data do not support the use of fully covered metal stent as first line treatment. 
 
BACKGROUND 
Biliary complications are reported in up to 35% of patients following liver 
transplantation. The stricture of duct-to-duct anastomosis is the most common complication 
in such patients (1) leading to liver dysfunction. Endo-therapy is considered the reference 
standard treatment for this condition due to the possible incidence of only a few major 
complications (1). While waiting for the release of international guidelines, the type of 
endo-therapy is center-based, according to local expertise. Across Europe, only a few high-
volume tertiary centers have reported data on the follow-up of patients who underwent 
different endo-therapies (2-4). A larger database would be of great interest in order to 
better illustrate the types of proposed endo-therapies and the results of these approaches 
on a wider national basis. With the aim of building a larger team for future guidelines, the 
BASALT working study group was set up among the active endoscopic units at Liver 
Transplantation Centers across Italy in 2013. The aims of the present study are to 
retrospectively analyze the available data on the workload and types of endo-therapies 
dedicated to the anastomotic stricture of liver transplanted (LT) patients, and to report the 
medium-term outcome data of this national series. 
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MATERIALS AND METHODS 
Patient selection 
A dedicated electronic datasheet was designed by one Author (P.C.) and then 
independently reviewed by another two Authors (R.R. and R.P.) to collect the characteristics 
of secreted LT patients who had undergone endoscopic management in 2013 (i.e. age, sex, 
ethiology of cirrhosis, time from liver transplantation, first- and second-line treatment 
types, radiological and clinical outcomes). LT patients managed with non-endoscopic first-
line treatments (radiology or surgery) were excluded. All the participants signed the 
informed consent form. The selection criteria for anastomotic stricture were homogenous 
among all centers, as recently assessed by a national survey among the same endoscopic 
units (BASALT study group) working with the Italian Liver Transplantation Centers (5), LT 
patients were considered for anastomotic stricture treatments in case of any alteration of 
liver tests persisting within three months and magnetic resonance or Kehr cholangiography 
being consistent with anastomotic stricture. Severity of the stricture was defined according 
to international criteria. In brief, severe stricture was defined in case of a reduction of the 
diameter of the common bile duct by more than 90% at the level of the anastomosis, while 
mild stricture in case of a reduction by less than 90%. 
Endoscopic therapy 
Endoscopic retrograde cholangiopancreatographies (ERCPs) of LT patients were 
planned under deep sedation (i.v. propofol, or general anaesthesia) in most units (75%), 
with conscious sedation (i.v. midazolam and petidine) performed in the remaining units 
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(25%). In 14 centres, aminosalicylic acid was used as the preventive medical therapy for 
hepatic artery thrombosis, and in 10 centers aminosalicylic acid was stopped before the 
ERCPs of LT patients. Sphincterotomy was performed before any first-line stenting 
procedure. 
The choice of stenting type depended on local expertise and the availability of stents 
at the time of endo-therapy. When multistenting was applied, 89% of units progressively 
increased the number of plastic stents at three-month intervals and, as for the remaining 
units (11%), at the occurrence of obstructive symptoms. At 81% of units, all the stents were 
removed at every session, whereas in 19% of units only the dysfunctional ones (clogging, 
partial migration) were removed. 
When a metallic stent was considered, a fully covered model was always chosen to secure 
its easy removal at the end of endo-therapy. Anti-migration systems were not available to 
all units during 2013 and brand types were varied among the units and not defined by 
protocol. The maximum number of plastic stents and the diameter of fully covered SEMS 
were assessed according to the diameters of the native and donor common bile ducts. 
Balloon dilation was used at the endoscopists’ discretion, as assistance to any stenting and 
to facilitate the increase of multistenting. The treatment duration for multistenting and 
metal stenting depended on each endoscopists’ preference. In the five units using single 
stenting, the stent was changed by protocol at three-month intervals in two units, and in the 
other three units when obstructive symptoms were identified. The success of endo-therapy 
was assessed by radiological criteria in 14 units (88%), including the duct diameter at the 
anastomotic level being equal to the one below, the rapid flow of contrast medium through 
the anastomosis and the easy passage of a balloon catheter through the anastomosis. On 
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the contrary, Rx failure of the endo-therapy was considered. In the remaining two units, 
radiological criteria were combined with laboratory-clinical criteria (see below). In all of the 
units, clinical success was achieved in patients in whom there was absence of any new-onset 
increase of the laboratory markers of cholestasis secondary to anastomotic stricture and in 
those who did not need a re-treatment after stents removal. The follow-up strategies were 
different among centers (retrospective design). Timing of imaging tests, lab tests and clinical 
evaluations were also center-based ranging from three to six-months after LT and every six 
months thereafter. During follow-up imaging tests, i.e. magnetic resonance cholangiography 
and abdominal ultrasound, were also planned at the time of any new-onset alteration of 
liver tests with or without the occurrence of biliary obstructive symptoms. The diagnostic 
criteria for recurrent anastomotic stricture were the same as for de-novo anastomotic 
stricture. After the stenting period, treatment failure was assessed in case of any new-onset 
elevation of markers of cholestasis with or without obstructive symptoms associated with 
anastomotic stricture. After ruling out other possible relevant co-factors (HCV flare, chronic 
rejection, de novo autoimmunity, hepatic artery thrombosis), re-treatment was planned in 
such cases.  
 
 
 
Complications 
Peri-procedural complications were reviewed and defined according to the 
international guidelines (6). Post-ERCP pancreatitis (PEP) was assessed in cases of abdominal 
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pain of pancreatic origin within 24 hours of the procedure, with serum amylase > 3x of 
normal value and prolongation of hospitalization; severe pancreatitis in cases of prolonged 
hospitalization > 10 days (7). Cholangitis was diagnosed in the event of new-onset fever > 
38°C within 48 hours of the procedure; relevant bleeding was considered in the event of 
melena or hematemesis or of a drop in the level of hemoglobin, with need for transfusions 
or endoscopic hemostasis within ten days from ERCP. While waiting for the European 
guidelines to be published in 2014 (8), in 2013 the prophylaxis of PEP and sepsis were 
center-based. In particular, PEP prophylaxis was performed in 10 units and consisted in non-
steroidal anti-inflammatory drugs in 7 units (i.e. 100 mg suppository indometacin or 
diclofenac in 5 and 2 units, respectively, with i.v. gabesate mesilate in 2 units and pancreatic 
stenting in one); while in 6 units, no prophylaxis was systematically applied to LT patients. 
Finally, antibiotic prophylaxis for preventing sepsis in LT patients was performed in 11 units. 
The study was approved by the Ethics Committee of the Fondazione IRCCS Ca’ Granda, 
Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan (Italy) and endorsed 
by the National Committee of the Italian Society of Digestive Endoscopy (SIED). All the 
Endoscopy Units working with the 19 Liver Transplantation Centers in Italy were officially 
invited to take part in the survey.  
 
 
Statistical analysis 
Data were expressed as median (IQ range) or mean (+SEM). Student’s T and Chi 
square tests were used when appropriate to compare the patients’ characteristics among 
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multistenting, fully covered SEMS and single stenting and to assess any association between 
the types of endo-therapy and high-volume activity of the Centers, which is defined as >250 
ERCPs/year. Kaplan-Meier’s survival analysis was done for the clinical outcome of: a) the 
whole cohort after undergoing both first and second-line treatments, b) the three groups 
according to the type of endotherapy, separately for the first and second-line treatment. In 
the latter analysis, patients were considered from the start of treatments. Rx failures and 
anastomotic stricture recurrences comprised drop-out events. 
 
RESULTS 
Participating Endoscopic Units 
Sixteen (84%) out of the 19 units working with Italian Liver Transplantation Centers 
participated in the study. Eleven of the 16 units (69%) had high-volume workloads. All the 
endoscopists working at these units were experienced (> 1000 ERCPs/life). During 2013, a 
total of 6654 ERCPs were performed in the 16 units, ranging from 80 to 1133 ERCPs per unit 
(median 328). Two hundred and sixty LT patients underwent endo-therapy for duct-to-duct 
anastomotic stricture. In order to treat anastomotic stricture, 524 (7.9%) ERCPs out of a 
total 6654 (median/center 18; range 7-204) were performed. 
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Study LT population 
Complete data on 221 LT patients were received and reviewed by the coordinating center. 
Among this group of LT patients, 40 (18%) were excluded from the analysis. Of these 40, 20 
presented with biliary complications after liver transplantation other than anastomotic 
stricture; 15 had anastomotic stricture recurrence after a previous treatment with fully 
covered SEMS prior to 2013 (non-naïve patients); and 4 died during first-line endo-therapy. 
Patient deaths occurred three months after fully covered stenting and at 3, 7 and 27 months 
during single stenting first-line treatment, secondary to liver failure in three and to PEP-
related sepsis in the fourth case. This last case was included in the complication rate. In one 
case, the anastomotic stricture was not passed and the patient underwent surgery. The 
remaining 181 LT patients comprised the study population and their data were 
appropriately analyzed. Complete endo-therapy and follow-up data were available for all 
the LT study patients after reminders to participating centers, when required. Thirty-six LT 
patients were treated at the ISMETT Hospital Palermo, 27 at the Papa Giovanni XXIII 
Hospital Bergamo, 19 at the Niguarda Ca’ Granda Hospital Milan, 13 at the Gemelli Hospital 
Rome, 12 at the Cardarelli Hospital Naples, 11 at the Borgo Trento Hospital Verona, 10 at 
the United Hospitals Ancona, 10 at the Molinette Hospital Turin, 9 at the Ca’ Granda 
Maggiore Policlinico Hospital Milan, 7 at the Sant’Agostino Estense Hospital Modena, 7 at 
the Medical School Hospital Pisa, 6 at the Policlinico Modena, 4 at the INT Hospital Milan, 4 
at the Santa Maria della Misericordia Hospital Udine, 4 at the University Hospital Bari and  2 
at the Universital Hospital Padua. Characteristics of the study population have been 
summarized in Table 1. 
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First-line treatments 
Multistenting 
One-hundred and one LT patients (56%) underwent multistenting. A median 4 
ERCPs/patient (IQR 3-5) were performed (p<0.0001 vs covered SEMS and single stenting) 
and a median 4 (IQR 3-5) 10-Fr stents were placed as the maximum stenting procedure. The 
median duration of multistenting therapy was 9 (IQR 6-12) months (p<0.0001 vs SEMS). 
Radiological success was achieved in 89 patients (88%) (p<0.001 vs single stenting). 
Anastomotic stricture recurrence after radiological success was recorded for 10 patients 
(11%) (p<0.001 vs SEMS) after a median of 8 (IQR 4-9) months from the removal of all stents 
(Table 2). Re-treatment was needed in 22 patients (22%) because of radiological failure (12 
patients) or recurrent anastomotic stricture (10 patients) after radiological success. 
 
Fully covered SEMS 
Twenty-six LT patients (14%) were treated with fully covered SEMS as first-line endo-
therapy. A median of 2 ERCPs/patient (IQR 2-3) were performed (p<0.0001 vs plastic 
multistenting). A 10-mm metal stent was used in 24 patients (92%) and 8-mm metal stent 
was used in the remaining two (8%) patients. The median duration of metal stenting was 5 
(IQR 3-6) months. Radiological success was achieved in 23 patients (88%, p<0.05 vs SS). 
Anastomotic stricture recurrence after radiological success was recorded in 11 patients 
(48%) after a median of 20 (IQR 4-11) months (Table 2). Re-treatment was needed in 14 
patients (54%) for Rx failure (3 patients) or anastomotic stricture recurrence (11 patients). 
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Single stenting 
Fifty-four LT patients (30%) were treated with single stenting as first-line endo-therapy. At 
the time of the first procedure, a 10 Fr stent has been placed in 87% of single stenting LT 
patients, a 8.5 Fr and 7 Fr have been placed in 5.5% both, and a 11.5 Fr was used in 2% of 
cases. A median of 2 ERCPs/patient (IQR 1-3) were performed (p<0.0001 vs plastic 
multistenting) and a 10-Fr stent was used as the maximum diameter procedure in 94% of 
cases. The median duration of single stenting therapy was 4 (IQR 2-12) months. Radiological 
success was achieved in 33 (61%) patients (i.e. p< 0.001 vs plastic multistenting and p<0.05 
vs SEMS). Anastomotic stricture recurrence after radiological success was recorded in 9 
patients (27%) after a median of 9 (IQR 7-12) months. Re-treatment was needed for 30 
patients (56%) following Rx failure (21 patients) or anastomotic stricture recurrence (9 
patients). 
 
Second-line treatments 
Overall, re-treatment was required for 65 patients (36%) out of the 181 naïve LT patients. 
One patient was removed from the study as a result of death unrelated to endo-therapy. 
Endoscopic treatment was applied to 49 out of the 65 patients requiring re-treatment. 
Multistenting was performed in 12 patients, i.e. 25% of endoscopic re-treatments, after 
radiological failure (6 patients) or following anastomotic stricture recurrence (6 patients) in 
7 plastic multistenting patients; 4 fully covered SEMS patients and 1 single stenting patient 
of first-line endo-therapies. As second-line treatment, plastic multistenting achieved 
radiological success in all patients (Table 3). Fully covered metal stenting was performed in 
26 patients, i.e. 53% of re-treatments, after Rx failure (10 patients) or following anastomotic 
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stricture recurrence (16 patients) in 12 plastic multistenting patients, 6 SEMS patients and 8 
single stenting patients of first-line endo-therapies. Metal stenting achieved Rx success in 22 
(85%) out of the 26 patients treated with SEMS as second-line treatment. Single stenting 
was applied to 11 patients (in 22% of endoscopic re-treatments), after failure (5 patients) or 
following anastomotic stricture recurrence (6 patients) in 3 SEMS and 8 single stenting 
patients of first-line endo-therapies. Single stenting achieved Rx success in 7 cases (63%, 
p<0.05 vs plastic multistenting).  
Non-endoscopic treatments were proposed in the remaining 16 patients. In this series, 
surgery was performed in 14 patients (2 plastic multistenting and 12 single stenting 
patients) after Rx failure (12 patients) and following anastomotic stricture recurrence (2 
patients) in 7 units, 5 of which were high-volume ones. Percutaneous drainage was 
performed in 2 patients, after Rx failure of SEMS in one patient and single stenting in the 
other patient, respectively.  
 
Complications 
Complications were recorded following 51 of the 656 (7.8%) ERCPs performed on LT 
patients who underwent first-line or second-line endo-therapies to treat an anastomotic 
stricture. Considering the overall rate of complication, no difference between plastic 
multistenting and SEMS patients was found. PEP occurred after 17 of the 656 (2.6%) 
procedures, corresponding to 12 PEP episodes out of the 181 (6.6%) ERCPs performed on 
endoscopy-naïve patients and 5 PEP episodes out of 474 (1.1%) ERCPs performed on 
endoscopy-non-naïve LT patients (p<0.0001). One severe PEP occurred in one non-naïve 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
patient after a single stenting procedure, followed by sepsis of pancreatic origin leading to 
death, in spite of nonsteroidal anti-inflammatory prophylaxis. 
Cholangitis occurred in 27 out of the 656 (4.1%) ERCPs performed, specifically in 5 cases out 
of 181 endoscopy-naïve patients and in 22 cases after 474 procedures in endoscopy-non-
naïve patients (p=ns). All of these patients were successfully treated with antibiotics. 
Relevant bleeding occurred in 6 cases out of the 656 (0.9%) ERCPs performed, specifically in 
4 cases (2.2%) after sphincterotomy of naïve procedures and in 2 cases (0.4%) of non-naïve 
procedures (p< 0.05 vs naïve). Five of the 6 bleeding patients were not taking aminosalicylic 
acid therapy, whereas the remaining one was, at the time of the procedure. Thienopyridine 
platelet inhibitor and anticoagulation were stopped before ERCP in three and one LT 
patients, respectively and no bleeding, occured in this subgroup. 
Migration of metal stents occurred in 5 of the 27 (19%) treatments. In four cases migration 
occurred during first-line treatment, partial (duodenal) in three and complete in one. Re-
treatment was needed in three of such cases. In one LT patient complete migration 
occurred during second-line treatment and no re-treatment was needed. No intra-biliary 
migration was recorded. All metal stents which underwent migration were 10 mm-large. 
 
Clinical outcome and associated factors 
Overall, there was no need for surgery in 168 of the 181 (93%) LT patients with anastomotic 
stricture at a median of 25 months (IQR 15-34) following the end of endo-therapies (both 
first and second-line). In terms of intention-to-treat analysis, clinical success was achieved in 
91%, 89% and 84% of the whole cohort at 12, 24 and 36 months of follow-up, respectively 
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(Fig.1). When assessing first-line endo-therapies separately, at 12 months of follow-up 
clinical success was achieved for 94% of patients after multistenting, 88% after fully covered 
SEMS and 70% after single stenting (p<0.05 vs multistenting and SEMS); at 24 months of 
follow-up clinical success was achieved in 82%, 65% and 59% of patients; and at 36 months 
in 77%, 54% and 48%, respectively (Fig.2). When second-line endo-therapies have been 
assessed, clinical success was achieved at 12 months of follow-up for 92%, 100% and 100%, 
and at 24 months for 92%, 100% and 73% (p<0.05 vs multistenting) for multistenting, SEMS 
and single stenting patients, respectively (Fig.3). It is worth noting that fully covered SEMS 
performed better as second-line rather than first-line treatment, i.e. 100% vs 88% at 12 
months and 100% vs 65% (p<0.05) at 24 months, respectively. Alkaline phosphatase was 
371+32 before treatment, 220+29 at the end of treatment (p<0.0001 vs pre) and 175+26 at 
the end of the follow-up (p<0.0001 vs pre).   
Regarding the characteristics of LT patients or the types of endo-therapies used, only the 
maximum number of stents during multistenting was associated with a higher rate of clinical 
success at 22 months, i.e. 91% (40 out of 44 patients) in the non-maximal (<3) stent group vs 
100% (55 out of 55 patients) in the maximal (> 4) stent group (p<0.05). Severity of the 
stricture was not associated to type of treatment applied, radiological or clinical success. 
 
DISCUSSION 
Today endoscopic therapies (1, 9) are the first-line treatment option for biliary 
complications after liver transplantation, however randomized trials comparing radiologic or 
surgical therapy vs endo-therapy are not yet available in this area. This point is firmly 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
confirmed by our national survey. The endo-therapies carried out, in fact, avoided surgery 
or percutaneous drainage for more than 90% of LT patients of the present study. The most 
appropriate endoscopic treatment of anastomotic stricture is far from being established and 
standardized. Traditionally, the progressive increase of the number of plastic stents to insert 
is proposed in order to treat this condition and high success rates have been confirmed in 
several studies (3, 4). Recently Tringali et al. reported clinical success in 98% of 51 LT 
patients at 5.8 years after multistenting as first- and second-line treatment, with a median 
of 4 large bore stents at the time of maximal dilation (4). The drawback of the multistenting 
approach is consistent with the need for several treatment sessions, which impacts on the 
number of hospitalizations, patients’ compliance and, ultimately, on costs. More recently, 
fully covered metal stents have been approved for the treatment of benign strictures, with 
the certification of safe removal within 12 months for most of them (10). The rapid use of 
self-expandable stents with a progressive maximal diameter of 8 mm or 10 mm within 48 
hours would potentially be more attractive than multistenting with regard to reducing the 
number of endoscopic procedures (insertion and removal sessions), hospitalizations, overall 
treatment duration, thus leading to a reduction of overall costs.  
Randomized controlled trials comparing fully covered SEMS and plastic multistenting are 
few and numerically weak (11, 12). Kaffes et al. (11) prospectively treated 20 patients 
randomized to either treatment with a 80% clinical success after multistenting and 100% 
success after a short fully covered SEMS suspended into the common bile duct across the 
choledocho-choledocal stricture at 26 months of follow-up. Tal et al. (12) coordinated a 
multi-center prospective trial involving 5 European academic referral centers. In this study, 
48 LT patients were randomized for traditional multistenting (24 patients) or fully covered 
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(24 patients). Short-term clinical success was achieved in 96% and 100% of cases, 
respectively, after multistenting or after fully covered SEMS of different models, both at the 
endoscopists’ discretion. At a median of 17 months, re-treatment was needed in 10 patients 
after multistenting (5 patients) or after SEMS (5 patients). Contrary to this, a large case 
series focusing on the long-term follow-up of 70 LT non-naive patients showed a suboptimal 
61% success rate after fully covered SEMS during a longer follow-up period of 4 years (13). 
The present study represents the largest nationwide series of LT patients undergoing endo-
therapy reported to date. In 2013, in the Italian referral units actively treating biliary 
complications following liver transplantation, multistenting was the most common first-line 
approach for anastomotic stricture. Medium-term results have confirmed a high rate of 
clinical success after multistenting, at best in the case of patients with more than 3 stents 
placed side-by-side in the view at the time of maximal dilation of the stricture. In such cases, 
the optimal rate of clinical success was maintained at almost 2 years after the end of 
multistenting. This treatment with maximal stenting was proposed by 7 of the 16 units in 
the study period. While anticipating pertinent international guidelines, the enthusiastic use 
of fully covered SEMS has been recorded in the survey. According to the sparse literature 
data discussed above, clinical success significantly decreased over time when covered SEMS 
was applied as a first-line endo-therapy. The hypothesis that large-diameter SEMS may 
possibly impair the vascular support during the rapid expansion within 48 hours from 
delivery across a very narrowed stricture, thus leading to an ischemic damage of the biliary 
wall, has yet to be tested. This condition could be among the factors leading to the sub-
optimal clinical results of SEMS compared to multistenting, when proposed as the first-line 
treatment option. Our data have shown poor and similar results for fully covered and single 
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plastic stent, when used as first-line treatment, probably because of both the low number of 
LT patients in whom SEMS have been placed and the high rate of migration of these stents. 
On the contrary, SEMS potentially has an optimal performance rate when the anastomotic 
stricture is not yet expected to be strictly narrowed. The data on the use of covered SEMSs 
as second-line treatment possibly support this view. A recent systematic review (14) 
reported better results after multistenting or SEMS, if the duration was at least 12 or 3 
months, respectively. In the present survey, the duration of both treatments was 
appropriately planned in most units. 
In order to prevent relevant commercial sponsorship on the study, brand type was not 
established in the protocol for either plastic or metallic stents. All metal stents implanted 
were fully covered ones in order to secure easy removal within 6 months. The migration of 
covered metal stents was appropriately named the Achilles’s heel of the device (15), leading 
to its limited efficacy. While anti-migration systems are welcome, they were not available to 
all units at the time of the study and should be the object of testing in future studies. 
At the time of the survey (2013), single stenting was proposed as the first-line treatment 
with sub-optimal results in 5 of the units working with Liver Transplantation Centers, as 
expected. With the objectives of improving LT patients’ management in the meantime and 
abandoning the use of single stenting, three meetings have been held every year since 2013. 
During these meetings, a summary of the running data of the survey was discussed. 
Moreover, courses focused on the endo-therapies of this condition were delivered in one 
center.  
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Balloon dilation alone has previously proved to achieve short-term success in a minority of 
LT patients. Accordingly, in our series dilation has not been used alone, but only as an aid 
during stenting or to assist maximal increase of multistenting, at discretion of the 
endoscopist. 
Limitations lie in the retrospective design of the present study and the lack of randomization 
among endo-therapies, thus leaving questions still unanswered regarding the most 
appropriate endo-therapy for anastomotic stricture. The retrospective design rules out the 
chance to define by protocol which selection criteria to apply for endo-therapy and for 
confirmation of anastomotic stricture, leaving those criteria variable among the centers, 
thus mirroring everyday practice. In addition, the relevant variability among the units of the 
number of patients treated secondary to different annual liver transplantation workloads 
has precluded the opportunity of testing any characteristics of patients or anastomotic 
strictures against a better selection of LT patients for metallic stent or, alternatively, for 
traditional multistenting. At present, the choice of endo-therapies remains based on both 
the center and endoscopists’ discretion. 
In summary, the present survey supports endo-therapy as the first-line approach for the 
treatment of anastomotic stricture by means of the overall valuable clinical results achieved, 
but on the basis of the aforementioned limitations, the present data are not conclusive in 
terms of defining the most appropriate endo-therapy as first- and second-line treatments. 
Among the endo-therapies utilised, multistenting has achieved optimal clinical results at 
medium-term follow-up and covered metal stenting can represent a good option as a 
second-line treatment. On the contrary, single stenting should be avoided secondary due to 
sub-optimal results. Randomized studies should be carried out to identify which LT patients 
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are treated best with the traditional plastic multistenting vs metallic stenting as first- and 
second-line endo-therapies. 
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Figure legends 
Fig.1. Kaplan-Meier’s survival analysis of the clinical success rate, including overall endo-
therapies for anastomotic stricture. Rx failures and anastomotic stricture recurrences 
comprised drop-out events. 
Fig.2. Kaplan-Meier’s survival analysis of the clinical success rate divided according to types 
of first-line endo-therapies. Rx failures and anastomotic stricture recurrences comprised 
drop-out events. 
Fig.3. Kaplan-Meier’s survival analysis of the clinical success rate divided according to types 
of second-line endo-therapies. Rx failures and anastomotic stricture recurrences comprised 
drop-out events. 
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Table 1. Characteristics of study population.  
 
 
OLT: orthotopic liver transplantation; HCC: hepatocellular carcinoma; PM: plastic multistent; CSEMS: covered 
self-expandable metal stent; SS: single stent. 
Data shown as percentage or median (IQ range) 
 
Overall 
(n=181) 
PM
(n= 101) 
CSEMS
(n =26) 
SS 
(n=54) 
p 
Age, yrs 59 (52 - 64) 59 (20 – 76) 61 (38 – 68) 60 (25 – 70)  
Sex, (M %) 82 83 70 87 ns
Viral etiology (%) 77 83 100 67 ns
HCC (%) 23 17 50 33 ns
Time from OLT, mos 4 (3 – 9) 4 (3 – 8) 8 (1 – 14) 14 (5 - 41) ns
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Table 2. First line endotherapies 
ERCP: endoscopic retrograde cholangiopancreatography; Rx: radiological; AS: anastomotic stricture; 
PM: plastic multistent; CSMES: covered self-expandable metal stent; SS: single stent. 
Data shown as percentage or median (IQ range) 
 
† vs PM 
‡ vs CSEMS 
 PM  
(n= 101) 
CSEMS 
(n =26) 
SS 
(n=54) 
p 
   
ERCPs/pt, n 4 (3 – 5) 2 (2 – 3)† 2 (1 –3)†  <0.0001†
Tp duration, mos 9 (6 – 12) 5 (3 – 6)† 4 (2 – 12)  <0.0001†
Rx Success, n (%) 89 (88) 23 (88) 33 (61)†‡ <0.001†/<0.05‡
AS recurrence, n (%) 10 (11) 11 (48)† 9 (27)‡ <0.001†/<0.05‡
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Table 3. Second line endotherapies 
 
Rx: radiological; AS: anastomotic stricture; PM: plastic multistent; CSEMS: covered self-expandable 
metal stent; SS: single stent  
 
† vs PM 
 
 PM  
(n= 12) 
CSEMS 
(n =26) 
SS
(n=10) 
p 
   
Tp duration, mos 9 (7 – 13) 4 (3 – 6)† 5 (2 – 13) <0.001† 
Rx success, n (%) 12 (100) 22 (85) 6 (60)† <0.05† 
AS recurrence, n (%) 0 (0) 0 (0) 0 (0) ns 
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